{
  "pmcid": "8733869",
  "sha256": "d8acd2ec9cab018f307ef756e1c3dc431aebd2fcacb13e62b201a35405f28101",
  "timestamp_utc": "2025-11-10T00:10:33.605666+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.190074886799028,
    "reading_ease": 35.96582288401257,
    "word_count": 261
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Normothermic Machine Perfusion in Liver Transplantation"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "This multicenter randomised clinical trial was conducted at 20 US liver transplant programs from November 2016 to October 2019."
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants were adults listed for liver transplant."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Donor livers were randomised 1:1 to OCS or ICS."
      },
      "Objective": {
        "score": 1,
        "evidence": "This trial evaluates whether the Organ Care System (OCS) Liver, a portable normothermic machine perfusion system, reduces early allograft dysfunction (EAD) and ischemic biliary complications (IBCs)."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was EAD incidence within 7 days posttransplant."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was via an Interactive Web Response System, with allocation concealment."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Blinding was not feasible for clinicians, but outcome assessors were blinded."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Of 300 randomised participants, 151 received OCS and 142 received ICS."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "The per-protocol analysis was used for effectiveness, while safety was assessed in the as-treated population."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The per-protocol analysis showed a significant reduction in EAD with OCS (18% vs 31%; P = .01)."
      },
      "Harms": {
        "score": 1,
        "evidence": "The mean number of liver graft-related severe adverse events within 30 days was noninferior in the OCS group compared to ICS."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "ClinicalTrials.gov Identifier: NCT02522871"
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 22,
    "max_score": 25
  }
}